Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (141-150 of 379) with videos related to

Pageof 38
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Journal of the National Cancer Institute|April 30, 2009
Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factorsNicole Skoetz, Olaf Weingart, Ina Monsef, et al.
British Journal of Haematology|April 26, 2017
Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibitionIda Hude, Stephanie Sasse, Paul J Bröckelmann, et al.
Leukemia & Lymphoma|January 26, 2010
Activity of cetuximab as single agent in a patient with relapsed multiple myelomaBoris Böll, Dennis A Eichenauer, Bastian Von Tresckow, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study GroupAndreas Josting, Sabine Wiedenmann, Jeremy Franklin, et al.
Hemasphere|November 15, 2019
Suicide in European Hodgkin Lymphoma PatientsAustin I Kim, Helen Goergen, Andreas Engert, et al.
Journal of the National Cancer Institute|July 22, 2011
Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myelomaKathrin Bauer, Michaela Rancea, Bettina Schmidtke, et al.
British Journal of Haematology|October 30, 2009
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphomaBoris Böll, Peter Borchmann, Max S Topp, et al.
Biological Chemistry|June 22, 2013
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitroMaike Sauer, Katrin S Reiners, Hinrich P Hansen, et al.
Pageof 38

Showing results (141-150 of 379) with videos related to

Sort By:
Pageof 38
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Journal of the National Cancer Institute|April 30, 2009
Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factorsNicole Skoetz, Olaf Weingart, Ina Monsef, et al.
British Journal of Haematology|April 26, 2017
Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibitionIda Hude, Stephanie Sasse, Paul J Bröckelmann, et al.
Leukemia & Lymphoma|January 26, 2010
Activity of cetuximab as single agent in a patient with relapsed multiple myelomaBoris Böll, Dennis A Eichenauer, Bastian Von Tresckow, et al.
Onkologie|February 13, 2008
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell, Markus Dietlein, Klaus Schomäcker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2003
Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study GroupAndreas Josting, Sabine Wiedenmann, Jeremy Franklin, et al.
Hemasphere|November 15, 2019
Suicide in European Hodgkin Lymphoma PatientsAustin I Kim, Helen Goergen, Andreas Engert, et al.
Journal of the National Cancer Institute|July 22, 2011
Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myelomaKathrin Bauer, Michaela Rancea, Bettina Schmidtke, et al.
British Journal of Haematology|October 30, 2009
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphomaBoris Böll, Peter Borchmann, Max S Topp, et al.
Biological Chemistry|June 22, 2013
Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitroMaike Sauer, Katrin S Reiners, Hinrich P Hansen, et al.
Pageof 38